The clearance is a step forward in AstraZeneca and Daiichi Sankyo’s plan to position antibody-drug conjugates like Enhertu ...

Mr. Finney brings 35 years of leadership, operations and corporate development experienceSOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE ...

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a biotechnology firm specializing in pharmaceutical preparations with a market capitalization of $1.12 billion, announced a recent change to its Board of ...

Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating yesterday.Invest with ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Valmet's Shareholders' Nomination Board updates its proposal for the composition and remuneration of the Board of Directors Valmet Oyj's stock exchange release on January 27, 2025 at 2:00 p.m. EET ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Vertex Energy, Inc. ("Vertex" or the "Company"), a leading specialty refiner and marketer of high-quality refined products, together with its affiliates, today announced it has successfully completed ...

A Waltham biotech focused on cystic fibrosis and a Boston biotech led by serial founder Gary Glick are the first ...

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced multiple program updates ahead of upcoming investor meetings in January, including the company’s scheduled ...